BMS invests $12m in cancer immunotherapy tie-up with Compuge...
Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo.<